Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Inovio Pharmaceuticals

Evaluate

Thumbnail
February 07, 2023

Bristol exit clips Dragonfly’s wings

Thumbnail
April 20, 2022

Arcturus’s latecomer Covid vaccine elicits little interest

Article image
Vantage logo
November 17, 2021

Atea’s woes grow while other Covid readouts approach

Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.

Article image
Vantage logo
September 03, 2021

No let-up in Covid-19 vaccine trials

A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.

Article image
Vantage logo
May 19, 2021

Glaxo’s Covid-19 effort progresses, this time thanks to Medicago

Article image
Vantage logo
May 11, 2021

Covid-19 vaccine leaders make hay while Novavax flounders

Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.

Article image
Vantage logo
April 22, 2021

Valneva joins the phase 3 Covid-19 vaccine club

Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.

Article image
Vantage logo
March 02, 2021

Inovio’s reinvention falls flat

The company’s claims of a win with its cervical precancer therapy candidate look questionable.

Article image
Vantage logo
February 01, 2021

Covid-19 vaccine pipeline builds as Clover and Dynavax push on

Article image
Vantage logo
December 31, 2020

Clinical developments over the Christmas period 2020

Trial results in Covid-19 and cancer emerge, but little promise is seen.

Article image
Vantage logo
October 22, 2020

The growing exposure to novel Covid-19 treatments

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up